conor douglas

science and technology studies academic, husband, dad, and overall swell guy

[GC Newsroom @NewsroomGC]

The Government of Canada announces investments of up to $1.5B over three years to increase access to, and affordability of, effective drugs for rare diseases.
https://t.co/mxY74DNIgV

[Social Pharmaceutical Innovation @SPIN_rare]

On Rare Disease Day SPIN Team Leader @cmwDouglas will present work entitled "Disrupting dominant bio-pharma industrial approaches to rare disease treatment through 'social pharmaceutical innovation' (SPIN)", as a part of the STS Departmental Seminar Series at York University.

[Social Pharmaceutical Innovation @SPIN_rare]

In our latest blog post Tineke Kleinhout-Vliek shows how decentralising clinical trials can be a form of social pharmaceutical innovation for rare disease treatment in Europe: https://t.co/iQxxto7cRZ

[LongwoodsNotes @LongwoodsNotes]

A central challenge facing drugs for #rarediseases is the production of robust evidence given the inherently small patient populations within each disease, writes @cmwDouglas in International Experiences & Made-in-Canada “Social Pharmaceutical Innovations”
https://t.co/UL8mb0N0uY

[LongwoodsNotes @LongwoodsNotes]

Expensive Drugs for Rare Diseases in Canada: What Value & At What Cost?
Latest issue of #HealthcarePapers is out. @bobnakagawa @DeanRegier @joel_lexchin @reformulary @oncology_bg @kjmeetswrld @haronba @bubela_tania @cmwDouglas @picardonhealth @kellygrant1
https://t.co/5uGlvWwkIc

[STS York University @STS_YorkU]

Passionate about the intersection of science, society, and policy? Apply now for a fully funded PhD or MA in Science and Technology Studies. International and domestic students welcome.
Click here to learn more: https://t.co/cstO5gB9gy

#scicomm #sts #YorkU #scicom #ststwitter

[STS York University @STS_YorkU]

Considering a career in academia? Applications are open for the largest and most diverse Science and Technology graduate program in Canada. Click here to learn how you could receive a fully funded MA or PhD degree: https://t.co/cstO5gB9gy #scicomm #sts #scicom #ststwitter

[Social Pharmaceutical Innovation @SPIN_rare]

In our latest blog post, @cmwDouglas shares some of the recent real-world ways that our research team has been involved in contributing to advancing, supporting, and inspiring #SPIN initiatives.

Read the full post here:
https://t.co/EoTwuvGzgS

#socialpharmaceuticalinnovation

[Social Pharmaceutical Innovation @SPIN_rare]

Our latest blog post presents a summary on the book 'From Big Pharma to Commons' by Gaëlle Krikorian - providing insight into #socialinnovation in rare disease from a French perspective

Read more here: https://t.co/vVYWXsmB5p

#raredisease #SPIN #socialpharmaceuticalinnovation

[BioCanRx - Canada's Immunotherapy Network @BioCanRx]

Chairs Douglas Mahoney, of @UCalgary & @cmwDouglas, of @YorkUniversity setting the stage for the plenary asking: What's the endgame for cancer #immunotherapy in Canada? #Summit4CI #CancerResearch

[Social Pharmaceutical Innovation @SPIN_rare]

#Crowdfunding is an increasingly common means of raising money for patients with #rarediseases around the world to access #expensive treatments - some see this as an act of #solidarity, others would disagree.

Read more about this in our latest blog post:
https://t.co/o493RVhuEO

[STS York University @STS_YorkU]

If you're interested in doing an #MA or #PhD in social studies of #science, #technology & #innovation then check out our #STS graduate program - now recruiting for Sept 2023! Each place has funding & their are C$6k & C$8k entrance scholarships too!
https://t.co/gn0NEghqvF

[conor douglas @cmwDouglas]

I'm excited to be presenting in the Health Symposium | 675: Social Pharmaceutical Innovation: Made-in-Canada solutions to address unmet medical needs for advanced therapeutics at CSPC 2022 https://t.co/mJ0x33HnRV @sched

[conor douglas @cmwDouglas]

@IStedman I had this exact conversation yesterday, about this graffiti. Either way it's a bad look, and wrong...whatever the student or prof or "teacher" might think.

[Social Pharmaceutical Innovation @SPIN_rare]

The first allogenic CAR-T treatment is one step closer to market authorisation, a development that is certain to have a substantial impact on treatment for patients with rare disease

Read more in our latest blog by @FaisalMohamedA

https://t.co/7rlW9tCanx

#raredisease #SPIN

[Social Pharmaceutical Innovation @SPIN_rare]

In our latest blog post, our Brazilian researcher @Marina_Borba discusses the term 'scientific colonialism' as it relates to rare diseases and the Global South.

Read more about this interesting and eye-opening discussion here: https://t.co/YrYnjdCcDc

#SPIN #RareDisease

[Social Pharmaceutical Innovation @SPIN_rare]

As a result of the #COVID19 pandemic, many countries are developing improved #genomic surveillance programs. Many in the #raredisease field are wondering what effect this may have on patients who rely on genomic sequencing for diagnosis.

Read more here:
https://t.co/ED933cOdJx

[Social Pharmaceutical Innovation @SPIN_rare]

In our latest blog post, Gengler, a guest writer talks about how we frame the issue of #drugs for #rarediseases and how these framings may help us better understand the problem.

Read more:
https://t.co/z2bve51tvl

#socialpharmaceuticalinnovation #SPIN #Lenalidomide #Revlimid

[York U Research & Innovation @YUResearch]

The Research Seminar Series in Science, Technology and Society will return for the 2022-23 academic year! Click to see a summary of seminars on a wide range of STS-related topics scheduled for this Fall! https://t.co/ZTx4rGFUxS | @YorkUScience @CDNJobar @GanaeleLanglois

[Social Pharmaceutical Innovation @SPIN_rare]

In our latest blog post, our research team identifies proof that alternative forms of research and development are possible by reflecting on the treatment for SPG50 which was found in Canada

Read more
https://t.co/IJotEM9AmU

#SPIN #socialpharmaceuticalinnovation #raredisease